ArticleAmerican journal of hematology2012
Prevalence of primary immune thrombocytopenia in Oklahoma.
Article in American journal of hematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Treatment of Critical Bleeds in Patients With Immune Thrombocytopenia: A Systematic Review.European journal of haematology · 2025Pooled it
- Pooled it
- Efficacy and safety of a new 10% intravenous immunoglobulin (IVIG) in Chinese patients with primary immune thrombocytopenia (ITP): a multicenter, single-arm, phase III trial.Clinical and experimental medicine · 2025Trial
- Pulmonary Involvement in Autoimmune-Mediated Disease.Deutsches Arzteblatt international · 2025Review
- The impact of anti-HBc positivity on clinical outcomes and treatment response in immune thrombocytopenia.Wiener klinische Wochenschrift · 2025Article
- Article
- Article
- Immune Thrombocytopenia Induced by Helicobacter pylori Infection: A Case Report and Literature Review.Cureus · 2025Article
- Chronic immune thrombocytopenic purpura in children: Clinical presentations and management.La Tunisie medicale · 2024Article
- Epidemiology of immune thrombocytopenia: study of adult patients at a referral hematology service in Northeastern Brazil.Hematology, transfusion and cell therapy · 2024Article
- Relationship between response to first-line steroid treatment in adult immune thrombocytopenic purpura and the course of the disease.Hematology, transfusion and cell therapy · 2024Article
- Implementation of Primary Immune Thrombocytopenia Clinical Practice Guidelines for Management of Pregnancy.Journal of clinical medicine · 2024Article
- Epidemiology, Treatment Patterns, and Cost Analysis of Immune Thrombocytopenia in Spain between 2014 and 2020: A Population-based Study.TH open : companion journal to thrombosis and haemostasis · 2024Article
- Treatment of critical bleeding events in patients with immune thrombocytopenia: a protocol for a systematic review and meta-analysis.Systematic reviews · 2024Article
- Trends in outcomes and racial disparities in adult hospitalizations for immune thrombocytopenia over a decade.Annals of hematology · 2023Article
- A Case of Vancomycin-Induced Severe Immune Thrombocytopenia.Hematology reports · 2023Article
- Older Adults and Immune Thrombocytopenia: Considerations for the Clinician.Clinical interventions in aging · 2023Review
- Article
- Assessment and Management of Immune Thrombocytopenia (ITP) in the Emergency Department: Current Perspectives.Open access emergency medicine : OAEM · 2022Review
- Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
To determine the prevalence of immune thrombocytopenia (ITP) in Oklahoma regardless of age, clinical characteristics, insurance status, and source of health care. Patients with ITP were identified by the administrative code ICD-9-CM 287.3 in Oklahoma hematologists' offices for a 2-year period, 2003-2004. Prevalence was estimated separately for children (<16 years old) and adults because of their distinct clinical characteristics. Oklahoma census data for 2000 was used as the denominator. Eighty-seven (94%) of 93 eligible Oklahoma hematologists participated; 620 patients with ITP were identified. The average annual prevalences were as follows: 8.1 (95% CI: 6.7-9.5) per 100,000 children, 12.1 (95% CI: 11.1-13.0) per 100,000 adults, and 11.2 (95% CI: 10.4-12.0) per 100,000 population. Among children and adults less than age 70 years, the prevalence was greater among women. Among adults aged 70 years and older, the prevalence was greater among men. The highest prevalence of ITP was among men age 80 years and older. These data document for the first time the prevalence of ITP regardless of age, clinical characteristics, insurance status, and source of health care. The methodology developed for this prevalence analysis may be adaptable for epidemiologic studies of other uncommon disorders which lack specific diagnostic criteria and are treated primarily by medical specialists. Am. J. Hematol. 2012. © 2012 Wiley Periodicals, Inc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.